Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
NCT03371108 is a phase 3 interventional trial sponsored by Gan and Lee Pharmaceuticals, USA. As of 21 Nov 2026, it is completed. It studies Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 2. The registry lists an enrollment of 567 participants at 57 sites in 1 country. The registry lists a start date of 31 Oct 2017 and a primary completion date of 17 Apr 2019.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03371108 |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional trial |
| Lead sponsor | Gan and Lee Pharmaceuticals, USA |
| Enrollment | 567 |
| Registered sites | 57 |
| Countries | 1 |
| Conditions | Diabetes Mellitus, Type 2 |
| Drugs | Gan & Lee Insulin Glargine Injection and Lantus® |
| Start | 31 Oct 2017 |
| Primary completion | 17 Apr 2019 |
| Study completion | 17 Apr 2019 |
| Last update posted | 1 Apr 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Elena A. Christofides, MD, FACE
Endocrinology Research Associates, Inc.
Principal Investigator - Jia Lu, PhD
Gan & Lee Pharmaceuticals, USA
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
57 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Simon Williamson Clinic
Birmingham
- University of Alabama at Birmingham
Birmingham
- Terence T. Hart, Md
Tuscumbia
- Family Practice Specialists
Phoenix
- Valley Research
Fresno
- the Rose Salter Medical Research Foundation
Newport Coast
- California Medical Research Association
Northridge
- Northern California Research Corp.
Sacramento
- Cmr of Greater New Haven, Llc
Hamden
- Chase Medical Research, Llc
Waterbury
- Meridien Research
Bradenton
- the Center for Diabetes and Endocrine Care
Fort Lauderdale
- Homestead Associates in Research
Homestead
- Biotech Pharmaceutical Group, Llc
Miami
- Genoma Research Group
Miami
- Miami Dade Medical Research Institute, Llc
Miami
- New Horizon Research Center
Miami
- Suncoast Clinical Research, Inc.
New Port Richey
- Peninsula Research
Ormond Beach
- Oviedo Medical Research
Oviedo
- Metabolic Research Institute
West Palm Beach
- River Birch Research Alliance, Llc
Blue Ridge
- Iresearch Atlanta
Decatur
- Sestron Clinical Research
Marietta
- Endocrine Research Solutions, Inc.
Roswell
- East-West Medical Research Institute
Honolulu
- Cedar Crosse Research Center
Chicago
- John H. Stroger Jr. Hospital of Cook County
Chicago
- Midwest Crc
Crystal Lake
- Iowa Diabetes and Endocrinology Research Center
West Des Moines
- Kentucky Diabetes Endocrinology Center
Lexington
- L-Marc Research Center
Louisville
- Activmed Practices and Research - Methuen
Methuen
- Palm Research Center, Inc.
Las Vegas
- Physicians East, Pa
Greenville
- Lillestol Research Llc
Fargo
- Aventiv Research, Inc.
Columbus
- Endocrinology Associates, Inc.
Columbus
- Primed Clinical Research
Dayton
- Mountain View Clinical Research
Greer
- Clinsearch - Clinical Research Specialists
Chattanooga
- University Diabetes & Endocrine Consultants
Chattanooga
- New Phase Research & Development
Knoxville
- Austin Regional Clinic
Austin
- Texas Diabetes & Endocrinology - Central Austin
Austin
- Texas Diabetes & Endocrinology - South Austin
Austin
- Sante Clinical Research
Kerrville
- Texas Diabetes & Endocrinology - Round Rock
Round Rock
- Clinical Trials of Texas
San Antonio
- Northeast Clinical Research of San Antonio
Schertz
- Radiant Research
Murray
- Wasatch Clinical Research, Llc
Salt Lake City
- Advanced Clinical Research
West Jordan
- Burke Internal Medicine & Research
Burke
- Stonesifer Clinical Research
Federal Way
- Rainier Clinical Research Center, Inc.
Renton
- Clinical Investigations Specialists-Wisconsin
Kenosha
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03371108
Each answer restates registry values shown on this page.
What is NCT03371108?
NCT03371108 is a phase 3 interventional trial sponsored by Gan and Lee Pharmaceuticals, USA. It studies Gan & Lee Insulin Glargine Injection and Lantus® in Diabetes Mellitus, Type 2.
Who leads NCT03371108?
The registry names Elena A. Christofides, MD, FACE (principal investigator, Endocrinology Research Associates, Inc.) and Jia Lu, PhD (study director, Gan & Lee Pharmaceuticals, USA) as overall officials.
Where does NCT03371108 run?
The registry lists 57 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03371108 study?
The registered drug and biological interventions are Gan & Lee Insulin Glargine Injection and Lantus®.
When did NCT03371108 end?
The registry lists a primary completion date of 17 Apr 2019 and a study completion date of 17 Apr 2019. The sponsor last updated the record on 1 Apr 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.